IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

The appointment comes as IceCure is experiencing strong commercial momentum for ProSense(R) in the United States and globally following U.S. Food and Drug Administration ("FDA") c ...

IceCure Medical Ltd. announced positive top-line results from its ICESECRET clinical trial of its ProSense cryoablation ...

CAESAREA, Israel, Jan. 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...

Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized ...

Icecure Medical ( (ICCM)) has shared an update. On March 19, 2026, IceCure Medical appointed veteran finance executive Meir Peleg as its new Chief Financial Officer, with his tenure set to begin on ...

Dedicated CIRSE focus session on the breast shows the growing interest from interventional radiologists to expand their practice to include care for breast cancer patients "We had a very successful ...

CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...

IceCure Medical (ICCM) announced the FDA’s Medical Device Advisory Committee Panel’s favorable recommendation with 9 panelists voting in favor and 5 voting against the benefit-risk profile of ...

Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had ProSense® cryoablation procedures ProSense® is FDA cleared and approved in ...